rosiglitazone has been researched along with Inflammatory Bowel Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Inman, RD; Lin, A; Pritzker, KPH; Streutker, CJ; Tsui, FWL; Tsui, HW; Zhang, Z | 1 |
| Atkinson, RD; Lee, JW; Lytle, C; Straus, DS; Tod, TJ; Vo, KT | 1 |
| Adachi, M; Gonzalez, FJ; Gumucio, DL; Kurotani, R; Madison, BB; Marin, HE; Morimura, K; Peters, JM; Sanford, M; Shah, Y; Young, HA | 1 |
| Fernández, PL | 1 |
| Bailey, ST; Flanigan, A; Jiang, W; Keilbaugh, SA; Lazar, MA; Murthy, S; Rangwala, SM; Su, CG; Wen, X; Wu, GD | 1 |
| Cai, TQ; Gan, X; Wong, B; Wright, SD | 1 |
6 other study(ies) available for rosiglitazone and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Lipocalin 2 links inflammation and ankylosis in the clinical overlap of inflammatory bowel disease (IBD) and ankylosing spondylitis (AS).
Topics: Animals; Ankylosis; Disease Models, Animal; Female; Humans; Inflammation; Inflammatory Bowel Diseases; Lipocalin-2; Male; Mice, Knockout; PPAR gamma; Rosiglitazone; Spondylitis, Ankylosing; Up-Regulation | 2020 |
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
Topics: Animals; Cytokines; Disease Models, Animal; Disease Progression; Female; Gene Expression Regulation; Hyperplasia; Hypoglycemic Agents; Inflammatory Bowel Diseases; Interleukin-10; Male; Mice; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease.
Topics: Animals; Colitis; Colon; Cytokines; Dextran Sulfate; Disease Susceptibility; Epithelial Cells; Female; Inflammatory Bowel Diseases; Intestinal Mucosa; Ligands; Mice; Mice, Transgenic; Polymerase Chain Reaction; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2006 |
[Stress and inflammatory bowell disease (I.B.D). Therapeutic strategies].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Translocation; Colitis, Ulcerative; Disease Models, Animal; Humans; Immobilization; Immunoglobulin A; Inflammatory Bowel Diseases; PPAR gamma; Prostaglandin D2; Prostaglandins; Rats; Rosiglitazone; Stress, Psychological; Thiazolidinediones; Time Factors | 2006 |
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.
Topics: Animals; Caco-2 Cells; Colitis; Cytokines; DNA-Binding Proteins; Epithelium; Gene Expression; HT29 Cells; Humans; I-kappa B Proteins; Inflammation; Inflammatory Bowel Diseases; Interleukin-8; Ligands; Mice; Microbodies; NF-kappa B; NF-KappaB Inhibitor alpha; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli.
Topics: Caco-2 Cells; Humans; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-1; Lipopolysaccharides; Matrix Metalloproteinase 9; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2001 |